3fca0833-b19b-47af-b75e-c9c45a99373b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57.7467488021903
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- OXIDATIVE_PHOSPHORYLATION+0.570
- MYC_TARGETS_V1+0.510
- MTORC1_SIGNALING+0.440
- DNA_REPAIR+0.410
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V2+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.380
- FATTY_ACID_METABOLISM+0.370
- PEROXISOME+0.360
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.460
- INFLAMMATORY_RESPONSE-0.330
- UV_RESPONSE_DN-0.330
- APICAL_SURFACE-0.280
- ALLOGRAFT_REJECTION-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- MYOGENESIS-0.250
- WNT_BETA_CATENIN_SIGNALING-0.230
- IL2_STAT5_SIGNALING-0.210
- IL6_JAK_STAT3_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516095 | — | — | 0.920 |
| 2 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.915 |
| 3 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.915 |
| 4 | SRR17866821 | — | — | 0.897 |
| 5 | 518420d3-dfdf-4163-99a4-2b8d7a04056c | — | — | 0.886 |
| 6 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.882 |
| 7 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.876 |
| 8 | SRR27320678 | — | — | 0.875 |
| 9 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.873 |
| 10 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| PEROXISOME | 0.360 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |